Pharmaceuticals & Medical Research
LIST1012Related Stocks
News
Today’s Market Recap: Markets Edge Up Amid Iran Conflict and Fed Rate Scrutiny
U.S. indices edged higher as investors weighed optimistic tech developments from Nvidia, Amazon, and Micron against a volatile geopolitical backdrop.
Rhythm Pharma's Drug Fails Key Genetic Obesity Trial, Shares Fall
March 16 (Reuters) - Rhythm Pharmaceuticals RYTM.O said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial.
What Are Defensive Stocks? Best Defensive Stocks to Buy in 2026
TradingKey - Defensives run on resilience: predictable demand, strong cash flow, conservative balance sheets, and tame volatility. You can’t just look at a sector name to find them. It requires a systematic examination of cash generation, leverage, dividend sustainability, beta, competitive moats, a
Hims & Hers Soars 64% in Three Days as Novo Nordisk Deal Opens Door to GLP-1 Market
TradingKey - Shares of Hims & Hers Health (HIMS.US) surged nearly 64% cumulatively over the first three trading days of this week, with an intraday rally of over 10% on Wednesday.
Novartis AG Stock (NVS) Moved Down by 3.16% on Mar 11: Drivers Behind the Movement
• Novartis stock declined due to trading ex-dividend for $4.773 per share. • Q4 2025 earnings beat expectations, but revenue missed analyst targets. • 2026 operating profit forecast projects a low single-digit percentage decline.
Should You Listen to Billionaires to Buy Moderna Stock in 2026?
A useful rule of thumb is to think of billionaire interest as a prompt to re-underwrite the story. Question: Can Moderna’s respiratory franchise stabilize and grow with flu, can the oncology pipeline provide a 2nd growth leg in a few years, and is the current valuation adequately discounting clinica
